U.S. markets close in 28 minutes
  • S&P 500

    4,275.62
    -12.43 (-0.29%)
     
  • Dow 30

    33,365.99
    -141.51 (-0.42%)
     
  • Nasdaq

    13,259.10
    +39.78 (+0.30%)
     
  • Russell 2000

    1,751.22
    -33.88 (-1.90%)
     
  • Crude Oil

    88.57
    -2.22 (-2.45%)
     
  • Gold

    1,845.60
    -20.50 (-1.10%)
     
  • Silver

    21.38
    -1.08 (-4.79%)
     
  • EUR/USD

    1.0492
    -0.0083 (-0.79%)
     
  • 10-Yr Bond

    4.6830
    +0.1100 (+2.41%)
     
  • GBP/USD

    1.2102
    -0.0099 (-0.81%)
     
  • USD/JPY

    149.7650
    +0.4350 (+0.29%)
     
  • Bitcoin USD

    27,820.20
    +719.47 (+2.65%)
     
  • CMC Crypto 200

    593.17
    -10.37 (-1.72%)
     
  • FTSE 100

    7,510.72
    -97.36 (-1.28%)
     
  • Nikkei 225

    31,759.88
    -97.72 (-0.31%)
     

Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie

Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie

While the overall market plummeted last year, shares of Vertex Pharmaceuticals (NASDAQ: VRTX) skyrocketed 31%. Here's why Vertex stock is an even better buy now thanks to AbbVie (NYSE: ABBV). AbbVie had been evaluating a triple-drug combo targeting cystic fibrosis (CF) in phase 2 testing.